Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the CDK4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer

Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the CDK4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer

US Patent 10328066 · Granted Jun 25, 2019

Estimated economic value: $16,009,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Therapeutic combinations comprising a c-RAF inhibitor2024
Combinations of MDM2 inhibitors with inhibitors of ERK for treating cancers2022
Pharmaceutical combinations2022
Therapeutic uses of a C-RAF inhibitor2021
Combination therapy2020
Pharmaceutical combinations2019
Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF2019
Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF2019
Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF2019
Androgen receptor mutation2018
Combination therapy2018
Pharmaceutical combination comprising binimetinib2018